Meet the study teams

Our research teams are comprised of world class microbiologists, scientists and researchers.

Feraro Trial

Dr Simon GoldenbergChief investigator

Dr Simon Goldenberg is a Consultant Microbiologist and Infection Control Doctor at Guy’s and St Thomas’ NHS Foundation Trust and Reader in Clinical Microbiology at King’s College London. He is the Chief Investigator for the FERARO trial, which is studying whether FMT can be helpful in patients with antibiotic resistant bacteria.
In 2015 he established an FMT programme to treat patients with recurrent Clostridioides difficile Infection (CDI) and developed an FMT donor bank using liquid and capsule preparations, which obtain an MHRA license in 2018
He is a member of the British Society of Gastroenterology Gut Microbiota for Health Expert Panel. He has co-authored the National and European guidelines on FMT Gut. 2018 Nov;67(11):1920-1941. doi: 10.1136/gutjnl-2018-316818. United European Gastroenterol J. 2021 Mar;9(2):229-247. doi:10.1177/2050640620967898.
Hi as an assistant editor of the Journal of Hospital Infection and Infectious Disease Reports.

Dr Blair MerrickTrial co-ordinator

Dr Blair Merrick is a Specialist Registrar in Infectious Diseases and General Internal Medicine at Guy’s and St Thomas’ NHS Foundation Trust. He is currently out of programme running the FERARO trial, which is forming the basis of his studies for a PhD at King’s College, London.

Promise Trial

Professor Debbie ShawcrossChief investigator

Group Head: Immunobiology of Chronic Liver Failure, Liver Sciences Research Synopsis: Patients with cirrhosis are predisposed to developing an infection which is frequently a precipitant of multiorgan failure and death. With poor outcomes following sepsis, the propagation of multidrug-resistant bacterial species and increasing waiting list mortality for liver transplantation, there is an urgent need for novel approaches to reducing the rate of infection. Paradoxically, these patients are characterised by heightened immune activity and rigorous inflammatory processes and are unable to contend with infection, suggesting that whilst these immune effectors are primed, their antibacterial effector functions are switched off. The precise mechanisms responsible for this phenomenon remain unknown but are suggestive of a skewed homeostatic balance between protective anti-pathogen immunity and host-induced immunopathology.

The aims of my research programme are to characterise the cellular and molecular mechanisms governing this predisposition to infection focusing on the intimate relationship between innate immune dysfunction and the gut-liver-brain axis. A dysfunctional gut microbiome plays a key role in patients with cirrhosis by influencing the rate of progression to terminal liver failure and a major goal for my group is to develop interventions which normalise the gut microbiome reducing the development of complications and liver failure. I consider myself at the forefront of this field of research and am a national and international key opinion leader on hepatic encephalopathy. I am the chief investigator of several key therapeutic clinical trials in the field including RIFSYS [NCT02019784] and PROFIT [NCT02862249].

Dr Lindsey EdwardsCo-investigator and research director

Lyndsey's academic career began on completing a Ph.D at UCL, investigating the role of the gut-microbiota in the aetiology of Crohn’s disease. I have completed Postdocs in mucosal immunology at the Institute of Child Health and at The Rayne Institute at UCL; before joining King’s College London in 2012. My research interests are in mucosal barrier immunology, host-microbe interactions, and subsequent priming of adaptive immune responses. Investigating how these interactions go awry as a pathogenic cofactor in intestinal & liver diseases.

Dr Simon GoldenbergCo-investigator

Dr Simon Goldenberg is a Consultant Microbiologist and Infection Control Doctor at Guy’s and St Thomas’ NHS Foundation Trust and Reader in Clinical Microbiology at King’s College London. He is the Chief Investigator for the FERARO trial, which is studying whether FMT can be helpful in patients with antibiotic resistant bacteria.
In 2015 he established an FMT programme to treat patients with recurrent Clostridioides difficile Infection (CDI) and developed an FMT donor bank using liquid and capsule preparations, which obtain an MHRA license in 2018
He is a member of the British Society of Gastroenterology Gut Microbiota for Health Expert Panel. He has co-authored the National and European guidelines on FMT Gut. 2018 Nov;67(11):1920-1941. doi: 10.1136/gutjnl-2018-316818. United European Gastroenterol J. 2021 Mar;9(2):229-247. doi:10.1177/2050640620967898.
Hi as an assistant editor of the Journal of Hospital Infection and Infectious Disease Reports.

Manmita RaiPROMISE Trial Manager

Email: promise@kcl.ac.uk

Versus Arthritis

Professor Matt Brown Chief investigator

Matt Brown is a clinician-scientist who trained initially in medicine and rheumatology in Sydney, Australia before completing a Doctorate of Medicine based at University of Oxford, focusing on genetics of ankylosing spondylitis. He was appointed Professor of Musculoskeletal Sciences at University of Oxford in 2004. In 2005 Matt returned to Australia, firstly to University of Queensland, and since 2016, at Queensland University of Technology, where he was Professor and Director of Genomics. In 2013 he was elected to Fellowship of the Australian Academy of Sciences in recognition for his achievements in genetics research. In 2019 he moved to King’s College London and Guy’s and St Thomas’ Hospitals NHS Trust to direct their NIHR Guy's and St Thomas' Biomedical Research Centre. He continues to work in genetics of human diseases, with a particular focus on common and rare bone and joint diseases, and in cancer genomics and personalized medicine. He continues to practice rheumatology, with a particular focus on spondyloarthritis.

Dr Simon Goldenberg FMT Transplant Unit Director

Dr Simon Goldenberg is a Consultant Microbiologist and Infection Control Doctor at Guy’s and St Thomas’ NHS Foundation Trust and Reader in Clinical Microbiology at King’s College London. He is the Chief Investigator for the FERARO trial, which is studying whether FMT can be helpful in patients with antibiotic resistant bacteria.
In 2015 he established an FMT programme to treat patients with recurrent Clostridioides difficile Infection (CDI) and developed an FMT donor bank using liquid and capsule preparations, which obtain an MHRA license in 2018
He is a member of the British Society of Gastroenterology Gut Microbiota for Health Expert Panel. He has co-authored the National and European guidelines on FMT Gut. 2018 Nov;67(11):1920-1941. doi: 10.1136/gutjnl-2018-316818. United European Gastroenterol J. 2021 Mar;9(2):229-247. doi:10.1177/2050640620967898.
Hi as an assistant editor of the Journal of Hospital Infection and Infectious Disease Reports.

Professor Deborah ShawcrossClinical expert, Fecal Microbiota Transplantation

Group Head: Immunobiology of Chronic Liver Failure, Liver Sciences Research Synopsis: Patients with cirrhosis are predisposed to developing an infection which is frequently a precipitant of multiorgan failure and death. With poor outcomes following sepsis, the propagation of multidrug-resistant bacterial species and increasing waiting list mortality for liver transplantation, there is an urgent need for novel approaches to reducing the rate of infection. Paradoxically, these patients are characterised by heightened immune activity and rigorous inflammatory processes and are unable to contend with infection, suggesting that whilst these immune effectors are primed, their antibacterial effector functions are switched off. The precise mechanisms responsible for this phenomenon remain unknown but are suggestive of a skewed homeostatic balance between protective anti-pathogen immunity and host-induced immunopathology.

The aims of my research programme are to characterise the cellular and molecular mechanisms governing this predisposition to infection focusing on the intimate relationship between innate immune dysfunction and the gut-liver-brain axis. A dysfunctional gut microbiome plays a key role in patients with cirrhosis by influencing the rate of progression to terminal liver failure and a major goal for my group is to develop interventions which normalise the gut microbiome reducing the development of complications and liver failure. I consider myself at the forefront of this field of research and am a national and international key opinion leader on hepatic encephalopathy. I am the chief investigator of several key therapeutic clinical trials in the field including RIFSYS [NCT02019784] and PROFIT [NCT02862249].